Y receptor antagonist

Compounds bearing imidazotriazole subunits have been investigated as neuropeptide Y receptor antagonists for the treatment of hyperphagia, obesity, and diabetes <2004W0050652>. 

Oxazolyl derivatives containing 1,2,4-oxadiazolyl-, 1,3,4-thiadiazolyl-, and 1,3,4-oxadiazolyl substituents, (I), were prepared by Cobb (1) and were effective as PPAR-y receptor antagonist and used in the treatment of diabetes, obesity, and metabolic syndrome disorders. 

Wieland, H.A. etal. (1995) Subtype selectivity and antagonistic profile of the nonpeptide Y receptor antagonist BIBP 3226. / Pharmact. Exp. Ther., 275, 143-149. 

Lundberg. J.M. etal. (1996) Recent developments with neuropeptide Y receptor antagonists. Trends Pharmacol. Sci.. 17, 301-304. 

Jacques, D., Cadieux, A., Dumont, Y Quirion, R. (1995) Apparent affinity and potency of BIBP3226, a non-peptide neuropeptide Y receptor antagonist, on purported Y1, Y2 and Y3 receptors. Eur.J. Pharmacol. 278, R3-R5. 

Daniels, A.J., Matthews, J.E., Slepetits, R.T., Jansen, M., Viveros, O.H., Tadepalli, A., Harrington, W., Heyer, D., Landavazo, A., Leban,J.J. Spaltenstein, A. (1995a) High affinity neuropeptide Y receptor antagonists. Proc. JVatl Acad. Sci. USA 92, 9067-9071. 

Grundemar, L. (1995) Will neuropeptide Y receptor antagonists offer new therapeutic approaches Exp. Opiti. Ther. Patents 5, 1007-1013. 

---